ARS Pharmaceuticals, Inc. Class Action Lawsuit
Company: ARS Pharmaceuticals, Inc.
Ticker: (NASDAQ) SPRY
Class Action Period: March 9, 2026 - June 24, 2026
How to Check Whether You May Be Eligible in the ARS Pharmaceuticals, Inc. Class Action
CLASS ACTION PERIOD
March 9, 2026 - June 24, 2026
Allegations
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the expected timeline for the expanded insurance coverage for neffy through CVS Caremark. On June 24, 2026, after the market closed, ARS published a press release announcing that the Company did not receive expanded insurance coverage for neffy through CVS Caremark by the guided July 1, 2026 deadline, which meant that ARS did not have expanded insurance coverage for neffy for the summer or back-to-school allergy seasons. ARS stated that CVS Caremark reserved its decision on the expanded insurance coverage for neffy until January 2027. On this news, investors and analysts reacted immediately to ARS’s revelation. The price of ARS’s common stock declined from a closing market price of $10.54 per share on June 24, 2026 to $8.02 per share on June 25, 2026, a decline of over 23.9% in the span of just a single day.
Eligibility
To be eligible for the lawsuit, you must have experienced a loss on ARS Pharmaceuticals shares purchased within the class period specified above.
Lead Plaintiff Deadline
If you suffered a loss in ARS Pharmaceuticals during the relevant time frame or pursuant to the relevant offering(s), you have until October 5, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Frequently Asked Questions
- How can ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) investors check whether their transactions may be relevant?
Investors whose purchases or acquisitions of ARS Pharmaceuticals, Inc. securities fall within the proposed class definition described above may submit their transaction details through this case page.
- Ensure your purchase falls within the class period
- Provide basic transaction and loss details
- Submit your information for review
The lead plaintiff deadline for this case is October 5, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. No action is required before this date to remain a potential class member.
- Who may be eligible for the ARS Pharmaceuticals, Inc. lawsuit?
Investors whose purchases or acquisitions of ARS Pharmaceuticals, Inc. securities fall within the proposed class definition described above and who suffered financial losses may be eligible.
- Could I still be eligible for the ARS Pharmaceuticals, Inc. lawsuit if I sold my shares?
Yes. Investors whose purchases or acquisitions fall within the proposed class definition may still be eligible even if they later sold their shares.
- How much compensation could I receive from the ARS Pharmaceuticals, Inc. lawsuit?
Any potential compensation would depend on the outcome of the case, the applicable class definition, and any settlement or judgment. If there is a recovery, eligible investors may receive a portion of it.
- What documents may be required for the ARS Pharmaceuticals, Inc. lawsuit?
Investors may be asked to provide transaction records, purchase and sale dates, number of shares, and loss details.
- Will I need to appear in court for the ARS Pharmaceuticals, Inc. lawsuit?
In most cases, investors do not need to appear in court. Whether an investor may need to participate personally depends on their role and developments in the case.
EXPLORE MORE CASES
Bloom Energy Corporation
BE
Bloom Energy Corporation BE Securities Class Action Lawsuit Update
Lead Plaintiff Deadline: September 28, 2026
Class Period: February 27, 2025 - July 8, 2026
Datavault AI Inc.
DVLT
Lead Plaintiff Deadline: October 5, 2026
Class Period: September 4, 2024 - October 30, 2025